- In an attempt to further make interventional cardiac procedures affordable, the National Pharmaceutical Pricing Authority (NPPA) is all set to cap the prices of other consumables used in angioplasty procedures in India.
- The NPPA on February 12, 2018 uploaded a circular saying they had recently conducted a trade margin analysis of the Cardiac Guidewire /Balloon Catherter and Guiding wire and found they were sold on huge profit margins, ranging from 150% to 400%.
- The NPPA conducted a meeting with various stake holders and manufacturing companies regarding the cost of making the consumables, landings costs, sale volumes, and the number of surgeries of each type across the country.
- It has asked the stakeholders to communicate their comments / view to NPPA by March 15, 2018. “The information is being put in public domain in recognition of the people’s right to information and also for introspection by the manufacturer/distributor/hospitals,” said Baljit Singh, Assistant Director, NPPA in the circular.
A trade analyst, on condition of anonymity welcomed the NPPA move saying, after the pricing authority capped coronary stents, the other important consumables prices went up to balance the profit margin. The analyst said, if the NPPA now caps the prices of these consumables, the overall cost of angioplasty will come down and become affordable.
Also, as the one-year validity of capping of prices of coronary stents by the National Pharmaceutical Pricing Authority (NPPA) is coming to an end on February 13. The drug price regulator conducted a crucial meeting on February 12, for revisiting the ceiling prices of coronary stents in the country.
- The other key decision over the pricing taken by the NPPA was to further cap the prices of coronary stents. As per the new circular dated February 12, 2018, the ceiling price of bare metal stents has been fixed at Rs 7,660, and that of drug-eluting stents and biodegradable stents at Rs 27,890 .
- The decision to revise the stent price was taken as the one-year validity of capping of prices of coronary stents by the NPPA is ending on February 13.
- The drug price regulator conducted a crucial meeting on February 12, for revisiting the ceiling prices of coronary stents in the country.
“Earlier, only stent prices were reduced and it did not have any major benefit for patients. Patients can be benefited only if prices of other consumables like balloon catheter and others are also reduced along with reduction in stent prices. I will support if government is reducing prices of other consumables along with stents,” said Dr Jagdish Hiremath, senior cardiologist at Ruby Hall Clinic, Pune and Immediate Past President of Cardiological Society of India.
He added,“Drastic reduction in prices might place hospitals in difficult position as it would amount to sudden loss of profit for them. This move will directly amount to loss of profit for hospitals and in that it would be hard for private hospitals to run their hospitals.”